The Landscape of Asthma Research in America
Asthma affects more than 25 million people in the United States, and the research community has responded with a wave of innovative studies. Right now, ClinicalTrials.gov lists hundreds of active asthma trials across the country, spanning everything from biologic injectables for severe eosinophilic asthma to digital health interventions that help children in urban clinics stick to their treatment plans.
The focus has shifted noticeably in recent years. Where older trials centered on basic inhaler comparisons, today's studies explore precision medicine approaches — matching specific therapies to the underlying type of airway inflammation a person has. Research centers like the American Lung Association's Airways Clinical Research Centers (ACRC) network now run trials at major institutions including Baylor College of Medicine in Houston, Columbia University in New York, and the University of Arizona in Tucson. These are not fringe experiments; they are federally funded or industry-sponsored investigations conducted under strict oversight.
One of the more active areas involves biologic therapies for severe asthma. Trials like the SOLAIRIA-2 study are testing GB-0895, an investigational medication administered every six months for adults and adolescents whose asthma remains uncontrolled despite using inhaled corticosteroids. Eli Lilly is evaluating brenipatide in a separate trial for moderate-to-severe asthma that runs approximately 65 weeks from screening through follow-up. The TRIM study, meanwhile, is looking at whether roflumilast — a drug already used for COPD — can help people with poorly controlled asthma and elevated BMI.
What this means for someone with asthma is straightforward: the range of asthma research studies recruiting right now is broader than many people realize. Some trials need participants with mild allergic asthma. Others specifically seek out people whose symptoms persist despite multiple medications. And a growing number are designed for children, particularly in urban communities where asthma rates run disproportionately high.
Who Can Join and What to Expect
The eligibility criteria vary widely, which is actually good news — it means there is likely a study suited to your situation. Most trials require a physician-confirmed asthma diagnosis and some degree of ongoing symptoms. Age cutoffs differ: many adult trials accept participants 18 and older, while pediatric studies like the PRAGMATIC trial in the Bronx focus on children between ages 2 and 12 with persistent or uncontrolled asthma.
Before you enroll, you will go through a screening process. At the University of Virginia's asthma research division, for example, screening involves a blood draw, allergy skin testing, and lung function tests across two to three visits. The research team shares test results with participants, so you walk away with useful information about your own health regardless of whether you qualify for the full trial.
Compensation structures vary. UVA offers screening compensation up to $125 for qualifying individuals. Epic Medical Research, which runs Phase II–IV asthma trials across multiple locations, provides financial compensation for time and travel as well as study-related medical evaluations at no cost. The exact amount depends on the trial's length, the number of in-person visits, and the procedures involved. Some trials compensate per completed visit; others provide a lump sum at the end. The COPD-OMA study through the American Lung Association, for instance, explicitly states that compensation is available for in-person visits to cover time and travel expenses.
One participant quoted by Epic Medical Research put it this way: "Being part of a clinical trial gave me hope. The doctors were incredible and I felt I was contributing to something bigger." That dual benefit — personal health monitoring plus contributing to medical knowledge — is a recurring theme in patient testimonials.
The time commitment can range from a few months to over a year. The SOLAIRIA-2 trial, for example, involves visits every one to two months after the first month, with the study treatment period lasting 52 weeks. Other trials may require more frequent visits early on and then taper off. Before signing up, you receive an informed consent document that spells out every visit, every procedure, and every potential risk. Reading it carefully and asking questions is not just encouraged — it is the entire point of the process.
Types of Asthma Trials: A Comparison
| Trial Type | Example Study | Typical Duration | Ideal For | What You Receive | Key Consideration |
|---|
| Biologic Medication | SOLAIRIA-2 (GB-0895) | 52 weeks | Severe uncontrolled asthma on ICS | Study medication, regular monitoring | Involves injections every 6 months |
| Oral Medication | TRIM (Roflumilast) | Varies | Poorly controlled asthma with elevated BMI | Daily diary + study drug | Oral pill, easier than injections |
| Inhaler Combination | Teva Fp/ABS Study | Several months | Adults with exacerbation history | Novel inhaler device | Tests two-in-one rescue + controller approach |
| Behavioral/Technology | PRAGMATIC (Bronx) | Multi-year | Children ages 2-12 in urban settings | Improved care coordination | Focuses on care delivery, not a new drug |
| Screening Studies | UVA Screening Protocol | 2-3 visits | Mild allergic asthma, confirmed by testing | Up to $125 for screening | No treatment; identifies candidates for future trials |
Finding the Right Trial: A Practical Approach
Searching for asthma clinical trials near me is the most common starting point, and ClinicalTrials.gov remains the most comprehensive database. But the sheer volume can be overwhelming. A better approach is to combine broad searches with targeted outreach to known research networks.
The American Lung Association ACRC network is a good place to look first. Their centers are located at respected academic hospitals and they post active recruitment listings on their website. Major hubs include Northwestern in Chicago, Mount Sinai in New York, Duke in North Carolina, and the University of Arizona in Tucson. If you live near any of these cities, you can contact the center directly — many have dedicated research coordinators who can walk you through what is currently enrolling.
Another path is through your own pulmonologist or allergist. Many specialists are either affiliated with research institutions or receive notifications about upcoming trials. Mentioning your interest during a regular appointment can open doors you might not find through online searches alone. Doctors often know which studies have a reputation for being well-run and which ones match their patients' specific clinical profiles.
For those without easy access to a major academic center, some trials offer telehealth components or hybrid models where only certain visits require in-person attendance. The COVID-19 pandemic accelerated this trend, and it has continued into the current research landscape. Ask about remote participation options when you speak with a study coordinator — it can make the difference between a trial that fits your life and one that does not.
What the Research Community Is Working On
Beyond the individual trials, several themes are shaping the direction of asthma research in the United States. One is the growing interest in eosinophilic asthma — a subtype driven by high levels of eosinophils, a type of white blood cell. Biologics like mepolizumab (now available in a self-administered prefilled syringe) emerged from earlier trials, and newer agents are being tested for the same population.
Another theme is the effort to address health disparities. The PRAGMATIC trial in the Bronx specifically targets urban children from communities where asthma rates and hospitalizations run well above the national average. By embedding a technology-based prompting system into primary care practices, the study aims to improve guideline-based care in settings that have historically been under-resourced. This kind of pragmatic clinical trial — conducted in real-world clinics rather than specialized research centers — is gaining traction because it answers questions that matter to everyday patients and their doctors.
There is also a push toward simplifying treatment regimens. The Teva fixed-dose combination inhaler trial, for instance, tests whether a single device that delivers both fluticasone propionate and albuterol sulfate can prevent asthma exacerbations more effectively than albuterol alone. If successful, it could reduce the number of inhalers patients need to carry and manage.
Making the Decision
Deciding to join a clinical trial is personal, and it helps to talk through the practical considerations with someone you trust — whether that is a family member, your primary care doctor, or a patient advocate. Ask the study coordinator specific questions: How many visits are required? What happens if I need to drop out? Will my insurance be billed for anything? Can I continue seeing my regular doctor during the trial?
The informed consent process is designed to answer these questions, but you should never feel rushed through it. A well-run trial will have a coordinator who welcomes your questions and gives you time to think. If something feels off — if the pressure to enroll is high or the explanations are vague — trust that instinct and look elsewhere.
Every medication on the pharmacy shelf today, from the most basic albuterol inhaler to the newest biologic injection, exists because someone before you volunteered to participate in research. The system is not perfect, and not every trial leads to a breakthrough. But for people with asthma who feel stuck between symptoms and the limitations of their current treatment, the research landscape in America offers a real, tangible option worth exploring.
研究の知恵